Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Shaala, I., Deghady, A., Meheissen, M., Elattar, N. (2025). EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN OVARIAN CANCER PATIENTS. ALEXMED ePosters, 7(1), 42-43. doi: 10.21608/alexpo.2025.360771.2096
Iglal Youssef Shaala; Akram Abdel Moneim Deghady; Mohamed Ahmed Meheissen; Nanees Nabil Elattar. "EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN OVARIAN CANCER PATIENTS". ALEXMED ePosters, 7, 1, 2025, 42-43. doi: 10.21608/alexpo.2025.360771.2096
Shaala, I., Deghady, A., Meheissen, M., Elattar, N. (2025). 'EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN OVARIAN CANCER PATIENTS', ALEXMED ePosters, 7(1), pp. 42-43. doi: 10.21608/alexpo.2025.360771.2096
Shaala, I., Deghady, A., Meheissen, M., Elattar, N. EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN OVARIAN CANCER PATIENTS. ALEXMED ePosters, 2025; 7(1): 42-43. doi: 10.21608/alexpo.2025.360771.2096

EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN OVARIAN CANCER PATIENTS

Article 1, Volume 7, Issue 1, January 2025, Page 42-43  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2025.360771.2096
View on SCiNiTO View on SCiNiTO
Authors
Iglal Youssef Shaala1; Akram Abdel Moneim Deghady2; Mohamed Ahmed Meheissen3; Nanees Nabil Elattar email 4
1Faculty of Medicine, University of Alexandria Clinical and Chemical Pathology Department
2Department of Clinical and Chemical Pathology, University of Alexandria
3Oncology and nuclear medicine deartment faculty of medicine, university of Alexandria
4Clinical pathology faculty of medicine alexandria university alexandria egypt
Abstract
Introduction
Ovarian cancer is considered one of the most common malignancies in females worldwide. Early detection of ovarian cancer will provide the patient with better chance of survival while discovering the disease at late stage will significantly increase the morbidity and the risk of complications. Hemostasis is a complex physiological process and to achieve normal hemostasis, delicate balance between clotting cascade and fibrinolytic cascade is required to prevent thrombosis or hemorrhage. Heparanase is an endoglycosidase enzyme which cleaves heparane sulphate, it is expressed in human tumors. Heparanase upregulation correlates with increased tumor vascularity and poor postoperative survival of cancer patients so heparanase is implicated in angiogenesis and tumor progression. It is now well established that the prime trigger to blood coagulation is tissue factor (TF) that is exposed on the surface of fibroblasts as a result of vessel wall injury. TFPI binds to factor Xa and, in this combination, binds to and inhibits tissue factor / factor VIIa complex and activated FX (FXa) and thus TFPI is currently being included as a natural coagulation inhibitor.
Aim of the work
The aim of this work was to investigate the relation of both heparanase procoagulant activity and tissue factor pathway inhibitor level with thromboembolic complications and metastasis in ovarian cancer patients.
Keywords
OVARIAN; TFPI; HEPARANASE
Supplementary Files
Statistics
Article View: 29